Abliva Financial Statements From 2010 to 2025

ABLI Stock  SEK 0.43  0.01  2.38%   
Abliva AB financial statements provide useful quarterly and yearly information to potential Abliva AB investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Abliva AB financial statements helps investors assess Abliva AB's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Abliva AB's valuation are summarized below:
Abliva AB does not presently have any fundamental signals for analysis.
Check Abliva AB financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Abliva AB's main balance sheet or income statement drivers, such as , as well as many indicators such as . Abliva financial statements analysis is a perfect complement when working with Abliva AB Valuation or Volatility modules.
  
This module can also supplement various Abliva AB Technical models . Check out the analysis of Abliva AB Correlation against competitors.

Abliva AB Company Shares Owned By Insiders Analysis

Abliva AB's Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.

Insiders Shares

 = 

Executives Shares

+

Employees

More About Shares Owned By Insiders | All Equity Analysis

Current Abliva AB Shares Owned By Insiders

    
  7.79 %  
Most of Abliva AB's fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Abliva AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
Competition

Based on the latest financial disclosure, 7.79% of Abliva AB are shares owned by insiders. This is 48.68% lower than that of the Healthcare sector and 45.06% lower than that of the Biotechnology industry. The shares owned by insiders for all Sweden stocks is 22.79% higher than that of the company.

Abliva AB Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Abliva AB's current stock value. Our valuation model uses many indicators to compare Abliva AB value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Abliva AB competition to find correlations between indicators driving Abliva AB's intrinsic value. More Info.
Abliva AB is rated fifth in return on equity category among its peers. It also is rated fifth in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Abliva AB's earnings, one of the primary drivers of an investment's value.

About Abliva AB Financial Statements

Abliva AB shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Abliva AB investors may analyze each financial statement separately, they are all interrelated. The changes in Abliva AB's assets and liabilities, for example, are also reflected in the revenues and expenses on on Abliva AB's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Abliva AB , a pharmaceutical company, engages in the research and development of mitochondrial medicine. Abliva AB was incorporated in 2000 and is headquartered in Lund, Sweden. Abliva AB is traded on Stockholm Stock Exchange in Sweden.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Abliva Stock Analysis

When running Abliva AB's price analysis, check to measure Abliva AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Abliva AB is operating at the current time. Most of Abliva AB's value examination focuses on studying past and present price action to predict the probability of Abliva AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Abliva AB's price. Additionally, you may evaluate how the addition of Abliva AB to your portfolios can decrease your overall portfolio volatility.